Loading…
← CockpitCompetitor Analysis › 688366.SS Shanghai Haohai Biological Technology Co., Ltd. Class AOpen in the cockpit ↗

Shanghai Haohai Biological Technology Co., Ltd. Class A688366.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Distributors
Momentum neutral 56
Mkt cap
$878M
US dollars, full cap
Free float
27%
of shares outstanding
$/day
$2.45M
20-day average traded
Fwd P/E
16.2×
forward earnings
ROIC−WACC
-5.3 pp
WACC 7.7%
Hurdle
+4 pp
Req g minus delivered
Next earnings
124 days
22 Mar 2027
Close · CNYCN¥28.00
1D-1.8%
1W-4.7%
1M-7.3%
3M-15.2%
6M-23.9%
YTD-36.2%
1Y-44.6%
ATR %3.0%
52w lowhigh47.0% off high

What Shanghai Haohai Biological Technology does

Employees: 2,110

Shanghai Haohai Biological Technology at a glance

Size Shanghai Haohai Biological Technology (688366.SS) is a China Health Care company (Medical Distributors) with a market value of $878M, the 2413th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥28.00 on 18 Nov 2026.

Performance Over six months the shares fell 23.9%, against -2.3% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue fell 9.4% over the last twelve months (peer median +5.3%); the operating margin is -2.1% (peer median 2.3%).

Valuation It trades at 16.2× forward earnings against a peer median of 15.3× (5th most expensive of 10).

Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 5.3 points below its cost of capital (7.7% WACC).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 99688366.SS 77
Six months, rebased to 100: Shanghai Haohai Biological Technology against the median of its 20 peers (local-currency closes).

Shanghai Haohai Biological Technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.28BCN¥2.46BCN¥2.68BCN¥2.64BCN¥2.12B
Revenue growth—-8%+2%+25%—
Gross profitCN¥1.60BCN¥1.60BCN¥1.74BCN¥1.74BCN¥1.32B
EBITDAn/aCN¥456MCN¥580MCN¥597MCN¥372M
Net incomeCN¥109MCN¥251MCN¥420MCN¥416MCN¥180M
Free cash flowCN¥272MCN¥458MCN¥362MCN¥402M-CN¥34.1M
Capital expenditureCN¥204MCN¥187MCN¥363MCN¥267MCN¥317M
Total debtCN¥433MCN¥398MCN¥453MCN¥408MCN¥118M

Quarterly statements and history in the cockpit →

Shanghai Haohai Biological Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%ENTERONEUARJO-B603368600713301584DOCM74766005876006283360301370RDC60513666170000784104688366.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai Haohai Biological Technology is the large dot.

Fundamentals: revenue growth against valuation

0%+20%20×40×ENTERONEUARJO-B603368747660058733608129688366.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai Haohai Biological Technology is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%ENTERONEUARJO-B60336830158474766005873360301370605136000078688366.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shanghai Haohai Biological Technology is the large dot.

Shanghai Haohai Biological Technology competitors and peer comparison

How Shanghai Haohai Biological Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai Haohai Biological Technology against its 20 peers (data as of 18 Nov 2026)
Measure688366.SSPeer medianRank in peer set
1-month return-7.3%-3.1%6th lowest of 21
6-month return-23.9%-2.3%6th lowest of 21
Distance from 52-week high-47.0%-20.2%4th lowest of 21
Revenue growth (TTM)-9.4%+5.3%4th lowest of 21
Operating margin-2.1%2.3%4th lowest of 21
Forward P/E16.2×15.3×5th most expensive of 10
Growth the price implies (Req g, 7 yrs)16.9%-1.2%4th most demanding of 16
Growth delivered (Del g)+13.2%+5.7%3rd highest of 16
Hurdle (Req g minus delivered)+3.8 pp-6.3 pp4th most demanding of 16
ROIC minus cost of capital-5.3 pp+0.0 pp6th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shanghai Haohai Biological Technology 688366.SSChina$878M-24%-9%-2%16.2×16.9%+13.2%
Entero Healthcare Solutions ENTERO.NSIndia$925M+60%+35%4%47.7×24.7%+29.9%
Neuca NEU.WAPoland$795M-9%+8%2%15.3×5.3%+8.1%
Arjo ARJO-B.STSweden$974M+42%0%8%21.1×-1.0%+3.9%
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%9.5×-9.7%+6.0%
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%n/an/an/a
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%n/a-2.7%+17.9%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%n/an/an/a
AS ONE 7476.TJapan$1.10B+25%+10%12%18.4×0.0%+6.3%
Shinva Medical Instrument 600587.SSChina$1.10B-10%+6%5%13.4×-6.9%+1.2%
Arata 2733.TJapan$576M-3%+3%1%12.0×-6.2%+3.8%
Shanghai New World 600628.SSChina$573M-10%-2%6%n/a-1.6%+1.0%
Ship Healthcare 3360.TJapan$1.38B+19%+6%3%14.6×-14.5%+7.6%
GKHT Medical Technology 301370.SZChina$525M-24%-11%1%n/a13.1%+7.5%
Redcare Pharmacy RDC.DEGermany$1.50B+53%+19%0%n/an/an/a
Toho 8129.TJapan$1.64B-5%+4%1%22.2×-4.6%+5.1%
Shanghai Lily & Beauty Cosmetics 605136.SSChina$449M-28%+5%2%n/a21.1%-18.1%
Thalys Medical Technology 603716.SSChina$446M-33%-43%-18%n/an/an/a
Gongwin Biopharm 6617.TWOTaiwan$412M+87%+12%-530%n/an/an/a
Shenzhen Neptunus Bioengineering 000078.SZChina$411M-48%-22%-1%n/a58.3%-7.8%
Excelsior Medical 4104.TWTaiwan$404M+5%+11%8%n/a-1.2%+5.7%

Questions

Which companies are Shanghai Haohai Biological Technology's closest peers?
The cockpit's peer set: Entero Healthcare Solutions (ENTERO.NS), Neuca (NEU.WA), Arjo (ARJO-B.ST), Guangxi LiuYao (603368.SS), Nanjing Pharmaceutical (600713.SS), Shanghai C and D INNOSTIC Medical Technology (301584.SZ), DocMorris (DOCM.SW), AS ONE (7476.T).
Is Shanghai Haohai Biological Technology expensive compared with its peers?
On forward p/e it trades at 16.2× against a peer median of 15.3×, 5th most expensive of 10 in its peer set. For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Shanghai Haohai Biological Technology stock performed?
Over six months to 18 Nov 2026 the shares returned -23.9% against -2.3% for the median peer; over one year -44.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.